Electrocore (ECOR) has disclosed a new risk, in the Innovation / R&D category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Electrocore faces material risk that its preclinical and clinical programs may be delayed, suspended, or terminated due to regulatory disagreements, patient enrollment challenges, operational deviations at CROs or trial sites, or safety and data‑integrity concerns. Such disruptions would extend development timelines for new indications, drive higher trial costs, and postpone or diminish the commercial potential of its gammaCore therapies.
The average ECOR stock price target is $15.00, implying 140.00% upside potential.
To learn more about Electrocore’s risk factors, click here.